OMCL OMNICELL, INC.
FY2025 10-K
OMNICELL, INC. (OMCL) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: medication management solutions and adherence tools primarily for healthcare systems and pharmacies in the U.S. market
- • No new product lines or segments introduced; company continues managing as a single operating and reporting segment
Management Discussion & Analysis
- • Revenue $1.185B in 2025, up $72.6M or 7% YoY from $1.112B in 2024; product revenues $665.7M (+6%), service revenues $519.1M (+8%)
- • ARR $636M in 2025, up from $580M in 2024; product bookings $535M in 2025, down from $558M in 2024
Risk Factors
- • Regulatory risk under privacy and data protection laws with potential compliance cost and liability exposure
- • Cybersecurity disruption risk involving information system breaches impacting business operations
Financial SummaryXBRL
Revenue
$1.2B
Net Income
$2M
Gross Margin
42.5%
Operating Margin
0.4%
Net Margin
0.2%
ROE
0.2%
Total Assets
$2.0B
EPS (Diluted)
$0.04
Operating Cash Flow
$127M
Source: XBRL data from OMNICELL, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on OMNICELL, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.